John F. DiPersio’s group evaluated the effect of JAK1/JAK2 inhibitors in an MHC-mismatched murine model and showed that JAK1/JAK2 inhibitors inhibited IFNR and IL-6R signaling, which inhibited migration of alloreactive T cells to GVHD target organs by decreasing expression of CXCR3. This evidence concerns the gene JAK2 and graft versus host disease.